NDA filings hold steady
The 116 NDAs received by CDER in calendar year 2005 continues a trend of modest growth since a user fee-era low of 98 NDAs received in 2001. The 2005 figure is comparable to the 115 NDA receipts in 2004, which was a modest bump from 109 in 2003 due to the transfer of therapeutic biologics to CDER in October 2003. The numbers have been revised from last year's figures, likely due to reclassification of the submissions; the previous NDA receipts were recorded as 103 for 2004 and 110 for 2003 (1"The Pink Sheet" April 4, 2005, p. 14). FDA has predicted continued modest growth in applications in fiscal 2006 and 2007, but the agency cautions that it does not expect high NDA receipts to translate into more approval (2"The Pink Sheet" Feb. 13, 2006, p. 6) ...
You may also be interested in...
FDA predicts an increase in applications over the next two years will not translate into more approvals within the fiscal 2006 and 2007 timeframe
The pharmaceutical industry is continuing to face declining output from its R&D investment
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.